294 related articles for article (PubMed ID: 15448016)
21. Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids.
Valsecchi M; Aureli M; Mauri L; Illuzzi G; Chigorno V; Prinetti A; Sonnino S
J Lipid Res; 2010 Jul; 51(7):1832-40. PubMed ID: 20194109
[TBL] [Abstract][Full Text] [Related]
22. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Sheikh MS; Shao ZM; Li XS; Ordonez JV; Conley BA; Wu S; Dawson MI; Han QX; Chao WR; Quick T
Carcinogenesis; 1995 Oct; 16(10):2477-86. PubMed ID: 7586155
[TBL] [Abstract][Full Text] [Related]
23. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure.
Cooper JP; Hwang K; Singh H; Wang D; Reynolds CP; Curley RW; Williams SC; Maurer BJ; Kang MH
Br J Pharmacol; 2011 Jul; 163(6):1263-75. PubMed ID: 21391977
[TBL] [Abstract][Full Text] [Related]
24. Activation of retinoic acid signalling after sciatic nerve injury: up-regulation of cellular retinoid binding proteins.
Zhelyaznik N; Schrage K; McCaffery P; Mey J
Eur J Neurosci; 2003 Sep; 18(5):1033-40. PubMed ID: 12956703
[TBL] [Abstract][Full Text] [Related]
25. Potent effect of 5-HPBR, a butanoate derivative of 4-HPR, on cell growth and apoptosis in cancer cells.
Han HS; Kwon YJ; Park SH; Kim EJ; Rho YS; Sin HS; Um SJ
Int J Cancer; 2004 Mar; 109(1):58-64. PubMed ID: 14735468
[TBL] [Abstract][Full Text] [Related]
26. 4-HPR modulates gene expression in ovarian cells.
Brewer M; Kirkpatrick ND; Wharton JT; Wang J; Hatch K; Auersperg N; Utzinger U; Gershenson D; Bast R; Zou C
Int J Cancer; 2006 Sep; 119(5):1005-13. PubMed ID: 16570282
[TBL] [Abstract][Full Text] [Related]
27. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
28. Alteration of retinol-binding-protein concentrations by the synthetic retinoid fenretinide in healthy human subjects.
Dimitrov NV; Meyer CJ; Perloff M; Ruppenthal MM; Phillipich MJ; Gilliland D; Malone W; Minn FL
Am J Clin Nutr; 1990 Jun; 51(6):1082-7. PubMed ID: 2140925
[TBL] [Abstract][Full Text] [Related]
29. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
30. Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.
Topletz AR; Tripathy S; Foti RS; Shimshoni JA; Nelson WL; Isoherranen N
Mol Pharmacol; 2015; 87(3):430-41. PubMed ID: 25492813
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide.
Jinno H; Steiner MG; Mehta RG; Osborne MP; Telang NT
Carcinogenesis; 1999 Feb; 20(2):229-36. PubMed ID: 10069458
[TBL] [Abstract][Full Text] [Related]
32. Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.
Cho HE; Min HK
J Pharm Biomed Anal; 2017 Jan; 132():117-124. PubMed ID: 27701038
[TBL] [Abstract][Full Text] [Related]
33. Molecular and metabolic retinoid pathways in the human ocular surface.
Nezzar H; Chiambaretta F; Marceau G; Blanchon L; Faye B; Dechelotte P; Rigal D; Sapin V
Mol Vis; 2007 Sep; 13():1641-50. PubMed ID: 17893666
[TBL] [Abstract][Full Text] [Related]
34. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
35. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
[TBL] [Abstract][Full Text] [Related]
36. Effect of NADPH-cytochrome P450 reductase on all-trans-retinoic acid efficacy and cytochrome P450 26A1 expression in human myeloid leukaemia HL-60 cells.
Hu L; Lv JF; Zhuo W; Zhang CM; Zhou HH; Fan L
J Pharm Pharmacol; 2016 Sep; 68(9):1193-202. PubMed ID: 27366899
[TBL] [Abstract][Full Text] [Related]
37. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
38. Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: evidence for reduced affinity of the complex for transthyretin.
Holven KB; Natarajan V; Gundersen TE; Moskaug JO; Norum KR; Blomhoff R
Int J Cancer; 1997 May; 71(4):654-9. PubMed ID: 9178822
[TBL] [Abstract][Full Text] [Related]
39. All-trans retinoic acid- and N-(4-hydroxyphenil)-retinamide-induced growth arrest and apoptosis in orbital fibroblasts in Graves' disease.
Pasquali D; Bellastella A; Colantuoni V; Vassallo P; Bonavolontà G; Rossi V; Notaro A; Sinisi AA
Metabolism; 2003 Nov; 52(11):1387-92. PubMed ID: 14624395
[TBL] [Abstract][Full Text] [Related]
40. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
